BRPI0923183A2 - derivados de ariciclopropilacetamida úteis como ativadores da glicoquinase - Google Patents

derivados de ariciclopropilacetamida úteis como ativadores da glicoquinase

Info

Publication number
BRPI0923183A2
BRPI0923183A2 BRPI0923183A BRPI0923183A BRPI0923183A2 BR PI0923183 A2 BRPI0923183 A2 BR PI0923183A2 BR PI0923183 A BRPI0923183 A BR PI0923183A BR PI0923183 A BRPI0923183 A BR PI0923183A BR PI0923183 A2 BRPI0923183 A2 BR PI0923183A2
Authority
BR
Brazil
Prior art keywords
aricyclopropylacetamide
derivatives useful
glycokinase activators
glycokinase
activators
Prior art date
Application number
BRPI0923183A
Other languages
English (en)
Inventor
Ana Belen Bueno Melendo
Francisco Javier Agejas-Chicharro
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0923183A2 publication Critical patent/BRPI0923183A2/pt
Publication of BRPI0923183A8 publication Critical patent/BRPI0923183A8/pt
Publication of BRPI0923183B1 publication Critical patent/BRPI0923183B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0923183-8A 2008-12-19 2009-12-11 Derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase, e composição farmacêutica BRPI0923183B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
EP08380341.1 2008-12-19
US15378109P 2009-02-19 2009-02-19
US61/153,781 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (3)

Publication Number Publication Date
BRPI0923183A2 true BRPI0923183A2 (pt) 2016-02-16
BRPI0923183A8 BRPI0923183A8 (pt) 2017-09-12
BRPI0923183B1 BRPI0923183B1 (pt) 2019-03-19

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923183-8A BRPI0923183B1 (pt) 2008-12-19 2009-12-11 Derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase, e composição farmacêutica

Country Status (34)

Country Link
US (1) US8063079B2 (pt)
EP (1) EP2379517B1 (pt)
JP (1) JP5497064B2 (pt)
KR (1) KR101290437B1 (pt)
CN (1) CN102256952B (pt)
AR (1) AR074470A1 (pt)
AU (1) AU2009335931B2 (pt)
BR (1) BRPI0923183B1 (pt)
CA (1) CA2746746C (pt)
CO (1) CO6382120A2 (pt)
CR (1) CR20110342A (pt)
DK (1) DK2379517T3 (pt)
DO (1) DOP2011000197A (pt)
EA (1) EA019055B1 (pt)
EC (1) ECSP11011150A (pt)
ES (1) ES2435242T3 (pt)
HR (1) HRP20130983T1 (pt)
IL (1) IL213210A (pt)
JO (1) JO2979B1 (pt)
MA (1) MA32902B1 (pt)
MX (1) MX2011006434A (pt)
MY (1) MY180567A (pt)
NZ (1) NZ592930A (pt)
PA (1) PA8851901A1 (pt)
PE (1) PE20120339A1 (pt)
PL (1) PL2379517T3 (pt)
PT (1) PT2379517E (pt)
SG (1) SG172256A1 (pt)
SI (1) SI2379517T1 (pt)
TN (1) TN2011000294A1 (pt)
TW (1) TWI395748B (pt)
UA (1) UA104742C2 (pt)
WO (1) WO2010080333A1 (pt)
ZA (1) ZA201103944B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
EP3072506B1 (en) 2013-11-22 2022-04-20 The University of Tokyo Carrier for drug delivery and conjugate, composition containing same, and method for administering same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083465A2 (en) 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
MXPA02010796A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.
JP3971189B2 (ja) 2000-05-08 2007-09-05 エフ．ホフマン−ラ ロシュ アーゲー ｐ−アミノ置換フェニルアミドグルコキナーゼ活性化物質
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4432901B2 (ja) * 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
AU2005235798A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
KR20080105180A (ko) 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
JP2008521864A (ja) * 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
BRPI0612582A2 (pt) * 2005-07-01 2010-11-23 Novartis Ag combinação de compostos orgánicos
MX2008000560A (es) 2005-07-11 2008-03-10 Mitsubishi Tanabe Pharma Corp Un derivado de oxima y sus preparaciones.
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
JP2009514835A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
EP1948645A1 (en) 2005-11-03 2008-07-30 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
EP2261216A3 (en) * 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivatives
PL2275414T3 (pl) 2008-04-28 2016-01-29 Kyorin Seiyaku Kk Pochodne cyklopentyloakryloamidu

Also Published As

Publication number Publication date
TWI395748B (zh) 2013-05-11
CR20110342A (es) 2011-09-14
CA2746746A1 (en) 2010-07-15
EA019055B1 (ru) 2013-12-30
ECSP11011150A (es) 2011-07-29
BRPI0923183B1 (pt) 2019-03-19
MY180567A (en) 2020-12-02
SI2379517T1 (sl) 2013-10-30
EP2379517B1 (en) 2013-08-28
HRP20130983T1 (hr) 2013-11-22
PA8851901A1 (es) 2010-07-27
CN102256952B (zh) 2013-12-11
JO2979B1 (en) 2016-03-15
KR20110086751A (ko) 2011-07-29
AR074470A1 (es) 2011-01-19
CN102256952A (zh) 2011-11-23
PL2379517T3 (pl) 2014-01-31
US20100160395A1 (en) 2010-06-24
BRPI0923183A8 (pt) 2017-09-12
JP5497064B2 (ja) 2014-05-21
PE20120339A1 (es) 2012-04-16
TW201029999A (en) 2010-08-16
ES2435242T3 (es) 2013-12-17
MA32902B1 (fr) 2011-12-01
DK2379517T3 (da) 2013-09-30
IL213210A (en) 2015-03-31
AU2009335931B2 (en) 2012-05-31
IL213210A0 (en) 2011-07-31
ZA201103944B (en) 2012-11-28
NZ592930A (en) 2013-01-25
KR101290437B1 (ko) 2013-07-29
JP2012512874A (ja) 2012-06-07
DOP2011000197A (es) 2011-09-15
TN2011000294A1 (en) 2012-12-17
EP2379517A1 (en) 2011-10-26
CA2746746C (en) 2013-09-24
UA104742C2 (uk) 2014-03-11
WO2010080333A1 (en) 2010-07-15
EA201170845A1 (ru) 2011-12-30
PT2379517E (pt) 2013-11-21
MX2011006434A (es) 2011-07-19
CO6382120A2 (es) 2012-02-15
AU2009335931A1 (en) 2011-07-07
US8063079B2 (en) 2011-11-22
SG172256A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
BRPI0818658A2 (pt) Derivados de piridina úteis como ativadores de glicoquinase
BRPI0912802A2 (pt) ativadores de glicoquinase
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI1014077A2 (pt) Derivados de tiazolilperidina como fungicidas
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
DK2397480T3 (da) Diazepindionderivat
BRPI0909782A2 (pt) Derivados de azetidina
DK2275414T3 (da) Cyclopentylacrylamidderivat
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI0920053A2 (pt) pirazolilaminopiridinas como inibidores da fak
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2648 DE 05-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.